Klaudija Viskovic

Dr. Klaudija Viskovic

University Hospital for Infectious Diseases "Dr Fran Mihaljevic", Zagreb, Zagreb, Grad, Croatia
+2
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
NKNarendra N. Khanna
Narendra N. Khanna
Mahesh A MaindarkarMahesh A Maindarkar
Mahesh A Maindarkar
VVVijay Viswanathan
Vijay Viswanathan
JFJosé Manuel Mattos Fernandes e Fernandes
José Manuel Mattos Fernandes e Fernandes
SPSudip Paul
Sudip Paul
JSJasjit S. Suri
Jasjit S. Suri
Motivation: The price of medical treatment continues to rise due to (i) an increasing population; (ii) an aging human growth; (iii) disease prevalence; (iv) a rise in the frequency of patients that utilize health care services; and (v) increase in the price. Objective: Artificial Intelligence (AI) is already well-known for its superiority in various healthcare applications, including the segmentation of lesions in images, speech recognition, smartphone personal assistants, navigation, ride-sharing apps, and many more. Our study is based on two hypotheses: (i) AI offers more economic solutions compared to conventional methods; (ii) AI treatment offers stronger economics compared to AI diagnosis. This novel study aims to evaluate AI technology in the context of healthcare costs, namely in the areas of diagnosis and treatment, and then compare it to the traditional or non-AI-based approaches. Methodology: PRISMA was used to select the best 200 studies for AI in healthcare with a primary focus on cost reduction, especially towards diagnosis and treatment. We defined the diagnosis and treatment architectures, investigated their characteristics, and categorized the roles that AI plays in the diagnostic and therapeutic paradigms. We experimented with various combinations of different assumptions by integrating AI and then comparing it against conventional costs. Lastly, we dwell on three powerful future concepts of AI, namely, pruning, bias, explainability, and regulatory approvals of AI systems. Conclusions: The model shows tremendous cost savings using AI tools in diagnosis and treatment. The economics of AI can be improved by incorporating pruning, reduction in AI bias, explainability, and regulatory approvals.

11 August 2021 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
Jasjit SuriJasjit Suri
Jasjit Suri
Sushant AgarwalSushant Agarwal
Sushant Agarwal
SGSuneet Gupta
Suneet Gupta
APAnudeep Puvvula
Anudeep Puvvula
KVKlaudija Viškovic
Klaudija Viškovic
DND. Subbaram Naidu
D. Subbaram Naidu
SARS-CoV-2 has infected over ∼165 million people worldwide causing Acute Respiratory Distress Syndrome (ARDS) and has killed ∼3.4 million people. Artificial Intelligence (AI) has shown to benefit in the biomedical image such as X-ray/Computed Tomography in diagnosis of ARDS, but there are limited AI-based systematic reviews (aiSR). The purpose of this study is to understand the Risk-of-Bias (RoB) in a non-randomized AI trial for handling ARDS using novel AtheroPoint-AI-Bias (AP(ai)Bias). Our hypothesis for acceptance of a study to be in low RoB must have a mean score of 80% in a study. Using the PRISMA model, 42 best AI studies were analyzed to understand the RoB. Using the AP(ai)Bias paradigm, the top 19 studies were then chosen using the raw-cutoff of 1.9. This was obtained using the intersection of the cumulative plot of “mean score vs. study” and score distribution. Finally, these studies were benchmarked against ROBINS-I and PROBAST paradigm. Our observation showed that AP(ai)Bias, ROBINS-I, and PROBAST had only 32%, 16%, and 26% studies, respectively in low-moderate RoB (cutoff>2.5), however none of them met the RoB hypothesis. Further, the aiSR analysis recommends six primary and six secondary recommendations for the non-randomized AI for ARDS. The primary recommendations for improvement in AI-based ARDS design inclusive of (i) comorbidity, (ii) inter-and intra-observer variability studies, (iii) large data size, (iv) clinical validation, (v) granularity of COVID-19 risk, and (vi) cross-modality scientific validation. The AI is an important component for diagnosis of ARDS and the recommendations must be followed to lower the RoB.

7 March 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
N.Nillmani .
Nillmani .
PJPankaj Kumar Jain
Pankaj Kumar Jain
NSNeeraj Sharma
Neeraj Sharma
MKMannudeep K. Kalra
Mannudeep K. Kalra
KVKlaudija Viškovic
Klaudija Viškovic
Jasjit SuriJasjit Suri
Jasjit Suri
Background and Motivation: The novel coronavirus causing COVID-19 is exceptionally contagious, highly mutative, decimating human health and life, as well as the global economy, by consistent evolution of new pernicious variants and outbreaks. The reverse transcriptase polymerase chain reaction currently used for diagnosis has major limitations. Furthermore, the multiclass lung classification X-ray systems having viral, bacterial, and tubercular classes—including COVID-19—are not reliable. Thus, there is a need for a robust, fast, cost-effective, and easily available diagnostic method. Method: Artificial intelligence (AI) has been shown to revolutionize all walks of life, particularly medical imaging. This study proposes a deep learning AI-based automatic multiclass detection and classification of pneumonia from chest X-ray images that are readily available and highly cost-effective. The study has designed and applied seven highly efficient pre-trained convolutional neural networks—namely, VGG16, VGG19, DenseNet201, Xception, InceptionV3, NasnetMobile, and ResNet152—for classification of up to five classes of pneumonia. Results: The database consisted of 18,603 scans with two, three, and five classes. The best results were using DenseNet201, VGG16, and VGG16, respectively having accuracies of 99.84%, 96.7%, 92.67%; sensitivity of 99.84%, 96.63%, 92.70%; specificity of 99.84, 96.63%, 92.41%; and AUC of 1.0, 0.97, 0.92 (p < 0.0001 for all), respectively. Our system outperformed existing methods by 1.2% for the five-class model. The online system takes <1 s while demonstrating reliability and stability. Conclusions: Deep learning AI is a powerful paradigm for multiclass pneumonia classification.

16 June 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Jasjit SuriJasjit Suri
Jasjit Suri
Sushant AgarwalSushant Agarwal
Sushant Agarwal
GCGian Luca Chabert
Gian Luca Chabert
Alessandro CarrieroAlessandro Carriero
Alessandro Carriero
APAlessio Paschè
Alessio Paschè
MKMannudeep K. Kalra
Mannudeep K. Kalra
Background: The previous COVID-19 lung diagnosis system lacks both scientific validation and the role of explainable artificial intelligence (AI) for understanding lesion localization. This study presents a cloud-based explainable AI, the “COVLIAS 2.0-cXAI” system using four kinds of class activation maps (CAM) models. Methodology: Our cohort consisted of ~6000 CT slices from two sources (Croatia, 80 COVID-19 patients and Italy, 15 control patients). COVLIAS 2.0-cXAI design consisted of three stages: (i) automated lung segmentation using hybrid deep learning ResNet-UNet model by automatic adjustment of Hounsfield units, hyperparameter optimization, and parallel and distributed training, (ii) classification using three kinds of DenseNet (DN) models (DN-121, DN-169, DN-201), and (iii) validation using four kinds of CAM visualization techniques: gradient-weighted class activation mapping (Grad-CAM), Grad-CAM++, score-weighted CAM (Score-CAM), and FasterScore-CAM. The COVLIAS 2.0-cXAI was validated by three trained senior radiologists for its stability and reliability. The Friedman test was also performed on the scores of the three radiologists. Results: The ResNet-UNet segmentation model resulted in dice similarity of 0.96, Jaccard index of 0.93, a correlation coefficient of 0.99, with a figure-of-merit of 95.99%, while the classifier accuracies for the three DN nets (DN-121, DN-169, and DN-201) were 98%, 98%, and 99% with a loss of ~0.003, ~0.0025, and ~0.002 using 50 epochs, respectively. The mean AUC for all three DN models was 0.99 (p < 0.0001). The COVLIAS 2.0-cXAI showed 80% scans for mean alignment index (MAI) between heatmaps and gold standard, a score of four out of five, establishing the system for clinical settings. Conclusions: The COVLIAS 2.0-cXAI successfully showed a cloud-based explainable AI system for lesion localization in lung CT scans.

31 March 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Jasjit SuriJasjit Suri
Jasjit Suri
SPSudip Paul
Sudip Paul
Mahesh A MaindarkarMahesh A Maindarkar
Mahesh A Maindarkar
APAnudeep Puvvula
Anudeep Puvvula
Sanjay SaxenaSanjay Saxena
Sanjay Saxena
KPKosmas I. Paraskevas
Kosmas I. Paraskevas
Parkinson’s disease (PD) is a severe, incurable, and costly condition leading to heart failure. The link between PD and cardiovascular disease (CVD) is not available, leading to controversies and poor prognosis. Artificial Intelligence (AI) has already shown promise for CVD/stroke risk stratification. However, due to a lack of sample size, comorbidity, insufficient validation, clinical examination, and a lack of big data configuration, there have been no well-explained bias-free AI investigations to establish the CVD/Stroke risk stratification in the PD framework. The study has two objectives: (i) to establish a solid link between PD and CVD/stroke; and (ii) to use the AI paradigm to examine a well-defined CVD/stroke risk stratification in the PD framework. The PRISMA search strategy selected 223 studies for CVD/stroke risk, of which 54 and 44 studies were related to the link between PD-CVD, and PD-stroke, respectively, 59 studies for joint PD-CVD-Stroke framework, and 66 studies were only for the early PD diagnosis without CVD/stroke link. Sequential biological links were used for establishing the hypothesis. For AI design, PD risk factors as covariates along with CVD/stroke as the gold standard were used for predicting the CVD/stroke risk. The most fundamental cause of CVD/stroke damage due to PD is cardiac autonomic dysfunction due to neurodegeneration that leads to heart failure and its edema, and this validated our hypothesis. Finally, we present the novel AI solutions for CVD/stroke risk prediction in the PD framework. The study also recommends strategies for removing the bias in AI for CVD/stroke risk prediction using the PD framework.